TY - JOUR
T1 - Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
AU - Issels, Rolf D
AU - Lindner, Lars H
AU - Verweij, Jaap
AU - Wust, Peter
AU - Reichardt, Peter
AU - Schem, Baard-Christian
AU - Abdel-Rahman, Sultan
AU - Daugaard, Soeren
AU - Salat, Christoph
AU - Wendtner, Clemens-Martin
AU - Vujaskovic, Zeljko
AU - Wessalowski, Rüdiger
AU - Jauch, Karl-Walter
AU - Dürr, Hans Roland
AU - Ploner, Ferdinand
AU - Baur-Melnyk, Andrea
AU - Mansmann, Ulrich
AU - Hiddemann, Wolfgang
AU - Blay, Jean-Yves
AU - Hohenberger, Peter
AU - European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
N1 - Copyright 2010 Elsevier Ltd. All rights reserved.
PY - 2010/6/1
Y1 - 2010/6/1
N2 - The optimum treatment for high-risk soft-tissue sarcoma (STS) in adults is unclear. Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region. Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone. We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy.
AB - The optimum treatment for high-risk soft-tissue sarcoma (STS) in adults is unclear. Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region. Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone. We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy.
U2 - 10.1016/S1470-2045(10)70071-1
DO - 10.1016/S1470-2045(10)70071-1
M3 - Journal article
C2 - 20434400
SN - 1474-5488
VL - 11
SP - 561
EP - 570
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 6
ER -